AR A >> WELCOME BACK AN EXPERIMENTAL CORONAVIRUS VACCINE BEING
DEVELOPED HERE IN THE U.S. IS
SHOWING PROMISE THE FIRST ROUND
OF HUMAN TEST FOUND THE VACCINE
TRIGGERED AN IMMUNE RESPONSE TO
ALL OF THE VOLUNTEERS WHO
RECEIVED IT, 45 OF THEM ROLLED
UP THEIR SLEEVES FOR THIS
VACCINE BACK IN MARCH.
RESEARCHERS SAY THEY HAD ONLY
MILD SIDE EFFECTS
THAT E CHILL SOME MUSCLE TO
PAIN KIND OF THE SAME THING YOU
SEE THAT YOU GET WHEN YOU HAVE
A FLU VACCINE.
SO THE NEXT STEP IS MUCH BIGGER
A 30,000 PERSON STUDY TO PROVE
THE SHOTS
ARE REALLY STRONG ENOUGH TO
PROTECT AGAINST THE CORONAVIRUS
AND THAT BEGINS LATER THIS
MONTH. SO JOINING US NOW TO
TALK ABOUT THIS NEWS
EPIDEMIOLOGIST DOCTOR JONATHAN
KANTOR AND THANK YOU FOR
TALKING WITH US TODAY.
SO THIS IS THE FIRST
VACCINE SHOWING PROMISING
RESULTS WHAT WAS THE REACTION
THAT HAS RESEARCHERS SO
OPTIMISTIC.
>> WELL THE REALLY EXCITING THING HERE IS THAT YOU KNOW WE ELICIT AN IMMUNE RESPONSE IN
EVERYBODY WHO RECEIVED THE
VACCINE. AND YOU KNOW IT SOUNDS
LIKE THE SORT OF AN OBVIOUS
THING, BUT THIS IS REALLY THAT
NECESSARY FIRST STEP THE
QUESTION IS CAN YOU GET THOSE
ANTIBODIES THAT WE NEED THAT WE
NEED TO FIGHT
THE CORONAVIRUS FROM GETTING
THE VACCINE AND THE ANSWER WAS
OVERWHELMINGLY. YES WE ALSO SAW
A DOSE RESPONSE RELATIONSHIP
WHAT THAT MEANS IS THAT THOSE
WHO GOT THE LOWER DOSE VACCINE
CREATED LESS ANTIBODIES AND
THOSE THEY GOT THE HIGHER DOES
CREATE MORE ANTIBODIES THAT
ALSO BOLSTERS THIS IDEA.
THE VACCINE
IS WORKING.
>> ALL RIGHT SO THERE HAS BEEN
SOME CONCERN THOUGH THAT THE
ANTIBODIES ASSOCIATED WITH
COVID-19 JUST LIKE OTHER
CORONAVIRUS SAYS DON’T STAY IN
THE BODY VERY LONG SO HOW COULD
THIS AFFECT THE EFFICACY OF THE
VACCINE.
>> RIGHT SO ONE OF THE CONCERNS IS THAT YOU KNOW WITH THE CORONAVIRUS HOW LONG YOU’RE
GOING TO GET THE DURABILITY OF
THE RESPONSE RIGHT SO YOU DON’T
WANT TO GET THE VACCINE EVERY
MONTH THAT’S NOT REALLY GOING
TO BE TENABLE ALTHOUGH IT SURE
BEATS THE HECK OUT OF GETTING
CORONAVIRUS SO WHAT WE’RE GOING
TO HAVE TO DO IS REALLY
INVESTIGATE CLOSELY TO SEE HOW
LONG THOSE ANTIBODY LEVELS LAST
THERE HAVE BEEN SOME REPORTS IN
THE LITERATURE OF PEOPLE GETTING CORONAVIRUS AFTER THEY’VE BEEN INFECTED BEFORE
BUT THOSE ARE VERY RARE AND WE
DON’T KNOW IF THOSE ARE JUST
BECAUSE MAYBE THE TESTING WAS
OFF ONE OF THE 2 TIMES THAT
THEY WERE TESTED.
SO HAVING THIS VACCINE DATE IS
ACTUALLY GOING TO HELP BECAUSE
WE CAN LAUNCH A TOTALLY STUDY
THOSE WHO HAVE ELICITED WHERE
WE HAVE A LIST IN ANYBODY
RESPONSE AND SEE HOW LONG DOES
THAT ANTIBODY RESPONSE LAST
AS WELL.
>>LAUREN VERNO: YEAH WHEN YOU
TALK TO JUST THE GENERAL PUBLIC
THERE ARE A LOT OF PEOPLE THAT
SAY HEY I’M NOT GOING TO TAKE A
FIRST OF ITS
KIND VACCINE. SO ARE THERE ANY
DANGERS WHEN CONSIDERING
WHETHER OR NOT YOU TAKE IT WHEN
THIS ULTIMATELY DOES BECOME
AVAILABLE.
>> SO THERE ARE ALWAYS RISKS WITH EVERYTHING AND THERE’S ALWAYS GOING TO BE A RISK
BENEFIT TRADEOFF THAT YOU HAVE
TO CONSIDER WITH
ANY TREATMENT AND THE THING
THAT WE CAN DO IS WE CAN LOOK
BACK AT THE PAST CENTURY A
VACCINE DEVELOPMENT AND FOR THE
MOST PART THE RISK BENEFIT
RATIO IS OVERWHELMINGLY IN
FAVOR OF THE IN GENERAL, YES
THEY’RE GOING TO BE RARE RISKS
ASSOCIATED WITH VACCINES.
BUT THE BENEFITS ARE GOING TO
BE SO MUCH GREATER THAT IT’S
DEFINITELY MAKE SENSE TO DO YOU
KNOW TO TAKE A VACCINE, YOU
KNOW HERE OF COURSE THE THING
TO KEEP IN MIND IS THAT UNLESS
YOU’RE IN A CLINICAL TRIAL,
YOU’RE NOT GOING TO BE AMONG
THE FIRST AS YOU MENTION,
THERE ARE 30,000 PEOPLE
PARTICIPATING IN THIS NEXT
TRIAL SO NO AMERICAN IS GOING
TO BE OFFERED THIS VACCINE
UNLESS IT’S BEEN TESTED OVER
30,000 PEOPLE BEFORE HAD SO
WE’RE GOING TO BE PRETTY ABLE
TO SAY YOU KNOW ARE PEOPLE
HAVING EVEN A RARE REACTION TO
MAKE SURE THAT IT’S A SAFE AND
EFFECTIVE AS POSSIBLE FOR ITS
ROLLED OUT TO THE AMERICAN
PUBLIC.
>>LAUREN VERNO: YEAH WE TALK
ABOUT THAT RISK VERSUS BENEFIT
SPECIALLY POSITIVE FOR PEOPLE
WHO
ARE VULNERABLE. SO THIS IS THE
FIRST ONE TESTED, BUT THERE ARE
MANY OTHERS IN
THE WORKS ABOUT THE PROCESS AS
FAR AS WHO COULD GET THERE
FIRST AND THEN COULD THERE BE
OTHER VACCINES THAT YOU COULD
TAKE AS WELL.
>> RIGHT SO YOU KNOW ONE OF THE THINGS HERE THAT’S INTERESTING IS THAT WE DON’T HAVE A SINGLE
RACE FOR A VACCINE, RIGHT THIS
ISN’T LIKE THE MANHATTAN
PROJECT IN WORLD
WAR 2, WHERE EVERYBODY KIND OF
GOT TOGETHER IN LOS ALAMOS AND
DEVELOP THE BOMB, YOU KNOW HERE
WE’VE GOT THE COMPANIES ALL
OVER THE WORLD THAT ARE TAKING
VERY
DIFFERENT APPROACHES THE
VACCINE THAT WE HAVE THIS
POSITIVE NEWS ON WHICH IS
MODERNA’S VACCINE. THIS IS AN
MRNA VACCINE.
THE OTHER THE IMPORTANT THING
HERE IS THAT THIS IS THE FIRST
TIME AND MRNA VACCINE HAS
REALLY BEEN SHOWN TO HAVE THIS
PROMISE THERE ARE NO MRNA
VACCINES THAT ARE REALLY IN
PRODUCTION RIGHT NOW SO
THAT’S KIND OF INTERESTING
EXCITING BECAUSE IT BODES WELL
FOR FUTURE DEVELOPMENT IN CASE,
A
FUTURE PANDEMICS AND THEN THERE
ARE A LOT OF OTHER COMPANIES
NAMELY IS ONE OF THE UNIVERSITY
OF OXFORD, WHICH IS REALLY BEEN
SHOWING A LOT OF PROMISE WHICH
IS SORT OF MORE OF A
TRADITIONAL A VACCINE
DEVELOPMENT ROUTES THAT A BIT
OF A HEAD START BECAUSE THEY’RE
ALREADY WORKING ON CORONAVIRUS
SCENES BUT TO GET THAT
REGULATORY APPROVAL. THE FDA IS
GOING TO REQUIRE THAT PEOPLE DO
THAT THE COMPANIES TO PHASE
3 TRIALS IN VERY LARGE NUMBERS
OF PEOPLE AS WE’RE SEEING AND
THE KEY THING THEY WANT TO
DEMONSTRATE THERE IS THE SAFETY
AND EFFECTIVENESS SO THEY WANT
TO
MAKE SURE THAT ARE THE PEOPLE
WHO ARE GETTING THIS VACCINE
LESS LIKELY TO GET CORONAVIRUS
NOT JUST CREATING ANTIBODIES
BUT ARE THEY LESS LIKELY TO
ACTUALLY GET THE DISEASE
BECAUSE THAT’S THE PRIMARY
ENDPOINT YOU’RE INTERESTED IN
NOT JUST MAKING ANTIBODIES BUT
MAKING SURE THAT YOU DON’T
GET INFECTED.
>>LENA PRINGLE: THAT’S
ULTIMATELY THE BOTTOM LINE
DOCTOR CANCER. THANK YOU SO